First Generic Version of COPD Inhaler Advair Diskus Approved by FDA

First Generic Version of COPD Inhaler Advair Diskus Approved by FDA

The first generic version of the inhalation treatment Advair Diskus (fluticasone/salmeterol powder) was recently approved by the U.S. Food and Drug Administration for chronic obstructive pulmonary disease (COPD) and asthma patients.

According to a press release from developer Mylan, the therapy, called Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), is indicated as a twice-daily breathing maintenance treatment for patients ages 4 and older. It will be available in three different dose strengths of fluticasone/salmeterol: 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg.

It is expected to launch in the second half of February following label amendments required by the FDA.

A generic therapy contains the same active components of an existing approved treatment. It functions just like the original patented product, is administered in the same way, and provides the same clinical benefits.

“Today’s approval of the first generic drug product for one of the most commonly prescribed asthma and COPD inhalers in the U.S. is part of our longstanding commitment to advance access to lower cost, high-quality generic alternatives,” Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research, said in an agency press release.

“Today’s approval will bring more competition to the market which will ultimately benefit the patients who rely on this drug,” she added.

Fluticasone is an anti-inflammatory agent that reduces swelling in the airways. Salmeterol is a vasodilator, meaning it relaxes and opens up the airways, facilitating breathing. Several studies have shown that the inhaled combination of the two alleviate COPD symptoms and improve the patient’s breathing ability.

The inhaler treatment has similar benefits in patients with asthma, another chronic lung disease characterized by shortness of breath, wheezing, and difficulty breathing.

Inhalers are considered a combination product because the medication is only compatible with a particular device. The FDA recognizes the challenges faced by companies developing generics for such complex products. Therefore, they have made available several resources that can help the companies streamline their process.

As part of the pre-ANDA program, representatives from the company can meet with FDA officers to seek guidance for the development of these products. FDA also provides publicly accessible guidance documents that explain the regulatory and clinical data requirements, formulation and device recommendations, and forms and application processes for various pharmaceutical products.

In 2013, the FDA published product-specific guidance for those attempting to develop a generic product for Advair Diskus, developed by GlaxoSmithKline.

“We are committed to advancing new guidance for sponsors to make the development of generic versions of complex products more efficient, and we’re prioritizing review of many applications covering proposed generic complex products for which a generic has not yet been approved,” said Anna Abram, deputy commissioner for policy, planning, legislation and analysis at the FDA.

Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others. She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University. She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
×
Vijaya Iyer is a freelance science writer for BioNews Services. She has contributed content to their several disease-specific websites, including cystic fibrosis, multiple sclerosis, muscular dystrophy, among others. She holds a PhD in Microbiology from Kansas State University, where her research focused on molecular biology, bacterial interactions, metabolism, and animal models to study bacterial infections. Following the completion of her PhD, Dr. Iyer went on to complete three postdoctoral fellowships at Kansas State University, University of Miami and Temple University. She joined BioNews Services to utilize her scientific background and writing skills to help patients and caregivers remain abreast with important scientific breakthroughs.
Latest Posts
  • Digital medical platform
  • Duaklir
  • Bevespi Aerosphere in Europe
  • SNG001
Print Friendly, PDF & Email

4 comments

  1. Mark Muraca says:

    Thank You Mylan!
    My wife has been on Advir for years, and since there was no generic, the insurance would charge a much higher co-pay.
    The Advir cost for a three month supply was greater than $630 for three months, and with insurance the co-pay was $186.
    Now with the generic Wyxela, the co-pay is $25 for three months.
    Now you can see why I said, “Thank You Mylan”!!

    • J SLAUGHTER says:

      Yeah this worked well…NOT. Went to the pharmacy to pick up my Advair 250/50 today and someone substituted the new generic. Now my co pay is $90 for one month for that whereas it used to be $27 for real ADVAIR. The pharmacist showed me the billing sheet and it shows the generic is over $390. The original ADVAIR was less – around $340. So who is winning on this one??? Big pharm again

  2. Ben Bennett says:

    I had to switch to this medication and within 3 days I started having chest tightness. I have been on Advair for 13yrs. I went from having to take it twice a day to once a day. My rescue inhaler had expired 2 years ago in my back pack which tells you how often I use it.
    Well guess what , I needed to use it.

    I had to be put on prednisone , saw that cycle through , had more exacerbation’s over the next couple weeks. Ended up needing an inhaler daily for the last 24 days.

    Had to do a nebulizer treatment 3 separate dates.. Both were severe attacks. People are going to die if they’re body is sensitive to the chemical and delivery changes.

    THIS PRODUCT IS NOT ADVAIR, AND IF YOUR BODY IS WORKING WITH ADVAIR , BE WARNED… THIS PRODUCT COULD KILL YOU. I was rushed to the ER in an ambulance having an asthma attack and I haven’t had that happen to me since I was 13yrs old. I’ve been stable with Advair for 13yrs. The second I switched to Wixela my life has been in jeopardy several times.

    I will reaching out to the companies to determine if formulations are identical, and the molecules are identical.

    I’m paying out of pocket full rate + GoodRx for my Advair.

    Wixela is saving money at the cost of peoples lives.
    Typical american pharma

  3. Angie says:

    My body doesn’t seem to react to generic drugs the same way it does to the brand-name ones, even though the medications are supposed to be identical.

    I just started taking the new generic inhaler for my asthma and don’t feel that it’s working as well as Advair, and I’ve been feeling extremely sleepy and even weak at times. This could possibly be related to other health issues but is more likely linked to the inhaler.

Leave a Comment

Your email address will not be published. Required fields are marked *